ARES TRADING S. A. By: /s/ Xxxxx Xxxxxxxxx Name: Xxxxx Xxxxxxxxx Title: Head of Legal Business Development Ares Trading S.A. By: /s/ Guillaume Vignon Name: Guillaume Vignon Title: Head of Immuno-Oncology Licensing & Business Development Vaccinex, Inc. By: /s/ Xxxxxxx Xxxxxxxx Name: Xxxxxxx Xxxxxxxx, Ph.D. Title: President & CEO [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Note: Reference to “Merck” in this document refers to the Group of Companies affiliated with Merck KGaA, Darmstadt, Germany. Appendix A PROTOCOL SUMMARY SYNOPSIS Study Number: [***] Title Phase 1b/2 Study of VX15/2503 in combination with avelumab in non-small cell lung cancer
ARES TRADING S. A., a private limited company incorporated under the laws of Switzerland, having its registered office at Zone industrielle de x’Xxxxxxxxx, 0000 Xxxxxxx, Xxxxxxxxxxx (“Ares”), (each of Delta, Beta, F-star, F-star GmbH and Ares being a “Party” and together the “Parties”; and each of Delta, Beta, F-star and F-star GmbH being an “F-star Party” and together the “F-star Parties”).
ARES TRADING S. A. By: Name: Title: Date: List of Exhibits
ARES TRADING S. A. By: /s/ Xxxxxx Xxxx Name: Xxxxxx Xxxx Title: Authorized Representative Ares Trading S.A. By: /s/ Xxxxxx Xxxxxx Name: Xxxxxx Xxxxxx Title: Authorized Representative Pfizer Inc. By: /s/ Xxxx Xxxxxxxx Name: Xxxx Xxxxxxxx Title: Global President, Oncology Checkmate Pharmaceuticals, Inc. By: /s/ Xxxxxxx X. Xxx Name: Xxxxxxx X. Xxx Title: General Counsel Appendix A PROTOCOL SUMMARY: Combination of CMP-001 with avelumab and/or Pfizer compounds Javelin Medley, Combination F Appendix A PROTOCOL SUMMARY: CMP-001 will be incorporated into the Javelin Medley study (B9991004), with avelumab as a backbone therapy for patients with PDx (anti-PD-1/L1) refractory SCCHN (squamous cell carcinoma of the head and neck). Upon successful achievement of the specific “Go” criterion for this doublet, separate patient cohorts will be evaluated with triplets of utomilumab/CMP-001/avelumab or PF-04518600/CMP-001/avelumab. Study Type: Phase 1b safety lead-in followed by Phase 2 expansion cohorts Rationale: For Combination F1, CMP-001 will be combined with avelumab. Since the combination of CMP-001 with pembrolizumab (anti-PD-1) showed significant anti-tumor activity in the setting of PDx-refractory melanoma, the goal of this study will be to assess the activity of CMP-001 in combination with avelumab as Combination F, Arm F in patients with PDx- refractory SCCHN. This disease has been selected for Combination F firstly because SCCHN is a type of tumor that responds to avelumab as a single agent, in a PDx pretreatment naive setting. However, after treatment with single agent PDx agents many of these patients are either found to have refractory disease or develop resistance. This may be in part due to a lack of an active immune tumor microenvironment. TLR9-responsive plasmacytoid dendritic cells have been observed in SCCHN, and injection of TLR9 agonist may “heat up” otherwise PDx refractory tumors. The anatomic location upon local recurrence as well sites of metastases are frequently feasible for intratumoral injections in this disease as well. If anti-tumor activity is noted in Combination F1, it is likely that the targets for 4-1BB or OX40 agonist antibodies will be induced on activated anti-tumor T cells in tumor-draining lymph nodes. There are scientific data to support the addition of utomilumab (4-1BB agonist) or an OX-40 agonist in combination with a TLR9 agonist (CMP-001) plus avelumab. TLR9 agonists will stimulate tumor DCs and these cells will traffic to tumor draining lymp...
ARES TRADING S. A., a corporation organized under the laws of Switzerland, located at Zone Industrielle de l’Ouriettaz, XX-0000 Xxxxxxx, Xxxxxxxxxxx (“ATSA”). Company and ATSA each may be referred to herein individually as a “Party” or collectively as the “Parties”.
ARES TRADING S. A. By: (signed) Xxxxx Xxxxxxxxx Name: Xxxxx Xxxxxxxxx By: (signed) Xxxx Xxxxxx Name: Xxxx Xxxxxx Exhibit A-1 EMD Serono Change of Ownership of NDA [REDACTED: Letter to U.S. FDX] Xxxxxxx X-0 EMD Serono Change of Ownership of IND [REDACTED: Letter to U.S. FDA] Exhibit B Xxxx of Sale This Xxxx of Sale (this “Agreement”) is entered into as of [ ], [ ], by and between EMD Serono, Inc., a Delaware corporation (“EMD Serono”), and Theratechnologies Inc., a corporation organized under the laws of the Province of Quebec (“Thera”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Termination Agreement (as defined below).
ARES TRADING S. A., a corporation organized and existing under the laws of Switzerland, having offices at Zone Industrielle de L’Ouriettaz, 117 Aubonne, Switzerland (the "Ares Trading");
ARES TRADING S. A., a Swiss company with its principal place of business at Xxxx Xxxxxxxxxxxx xx x’Xxxxxxxxx, 0000 Xxxxxxx, Xxxxxxxxxxx (the “Purchaser”),each a “Party” and together, the “Parties”.
ARES TRADING S. A. [***] with a copy, which shall not constitute notice, to: [***] Longitude Venture Partners IV, L.P. [***] Sofinnova Venture Partners X, L.P. [***] Alexandria Venture Investments, LLC [***] Citadel Multi-Strategy Equities Master Fund Ltd. [***] with copies to: [***] and [***] Fidelity Mt. Xxxxxx Street Trust: Fidelity Series Growth Company Fund [***] Fidelity Mt. Xxxxxx Street Trust: Fidelity Growth Company Fund [***] Fidelity Growth Company Commingled Pool [***] Fidelity Mt. Xxxxxx Street Trust : Fidelity Growth Company K6 Fund [***] Fidelity Select Portfolios: Biotechnology Portfolio [***] Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund State Street Bank & Trust [***] Octagon Investments Master Fund LP [***] GV 2017, L.P. [***] GV 2019, L.P. [***] KPCB Holdings, Inc. [***] Xxxx X. Xxxxxxx [***] Xxxxxx X. Xxxxx, as Trustee of the Xxxxxx Xxxxx 2010 Trust UA 10-26-2010 [***] Xxxxxxx X. Xxxxx [***] Xxxxxxxxxxx X Xxxxxx [***]
ARES TRADING S. A. By: /s/ Xxxxxx Loumaye By: /s/ Xxxxxx Xxxx Name: Xxxxxx Loumaye Name: Xxxxxx Xxxx Title: CEO Title: Authorized Representative By: /s/ Fabien de Ladonchamps By: /s/ Xxxxxxxxx Xxxxxx Name: Fabien de Ladonchamps Name: Xxxxxxxxx Xxxxxx Title: VP Finance Title: Authorized Representative [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. EXHIBIT A [*] [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
